LENSAR Inc (LNSR) is a publicly traded company in the Healthcare — Medical - Devices industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally.
Analysis Summary
LENSAR Inc reported revenue of $58.4M in the most recent fiscal year, growing at a 5-year CAGR of 17.2%.
Trailing-twelve-month margins: gross margin 48.0%, operating margin -13.5%, net margin 57.6%.
At the current price of $6.98, LNSR trades at a P/E of 5.44 and an ROE of 103.80%. Market capitalisation stands at $86M.
Balance sheet quality for LNSR: current ratio of 1.2, net cash position of $15.2M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $6.98 |
| Market Cap | $86M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 5.44 |
| Price / Book | 5.70 |
| EV / EBITDA | 2.65 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 10380.25% |
| Return on Invested Capital | -16.02% |
| Return on Assets | 49.88% |
| Gross Margin | 47.96% |
| Operating Margin | -13.48% |
| Net Margin | 57.57% |
Financial Health
| Debt / Equity | 0.16 |
| Current Ratio | 2.39 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -2.84 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| LNSR | LENSAR Inc | $87M | 5.44 | 5.70 | 103.8% |
| ABT | Abbott Laboratories | $177.1B | 32.49 | 3.45 | 10.5% |
| 0Y6X.L | Medtronic Plc | $125.7B | |||
| MDT | Medtronic plc | $118.5B | 22.97 | 2.39 | 10.6% |
| SYK | Stryker Corporation | $109.2B | 29.95 | 4.66 | 16.4% |
| 0R2S.L | Stryker Corporation | $107.9B | 29.27 | 4.55 | 16.4% |
| 0HOY.L | Boston Scientific Corporation | $66.5B | 48.91 | 5.86 | 11.9% |
| BSX | Boston Scientific Corporation | $65.3B | 17.73 | 2.61 | 14.9% |
Price Performance
| 1 month | -15.26% |
| 3 months | +20.91% |
| Year-to-date | -40.33% |
| 1 year | -45.22% |
| 3 years | +112.23% |
52-Week Range
| 52-week High | $12.94 |
| 52-week Low | $4.95 |
| Avg Volume (90d) | 103K |
Related companies: ANIK · ARAY · AVR · CRBP · CRDF · MXCT · OWLT
Explore sector: Healthcare · Medical - Devices
More sections of LNSR: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks